Lexeo Therapeutics, Inc. Common Stock (LXEO) Free Cash Flow
Lexeo Therapeutics, Inc. Common Stock (LXEO) free cash flow history and trends. Track FCF in Excel with MarketXLS.
Free Cash Flow Data
| Period | Free Cash Flow (USD) |
|---|---|
| 2021-12-31 | -$44.37M |
| 2022-12-31 | -$55.23M |
| 2023-12-31 | -$59.66M |
| 2024-12-31 | -$81.63M |
| 2025-12-31 | -$98.96M |
How LXEO compares with sector peers
| Symbol | Company | Free cash flow (latest fiscal year) |
|---|---|---|
| VTGN | Vistagen Therapeutics Inc. | -$66.44M |
| ALT | Altimmune Inc. | -$67.55M |
| ABEO | Abeona Therapeutics Inc. | -$84.30M |
| INO | Inovio Pharmaceuticals Inc. | -$88.92M |
| FLGT | Fulgent Genetics Inc. | -$124.21M |
These are five companies in the same sector as LXEO with a comparable annual free cash flow. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Lexeo Therapeutics, Inc. Common Stock Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Free_Cash_Flow("LXEO", 2025, "")
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | LXEO | $3.23 | +0.62% | 0.96M |
| 3 | ||||
| 4 | ||||
| 5 |